Monoclonal antibodies “for use in SubB2M immunoassays”, a vague description and in typical style of this management. Is it not the big advantage of SuB2M (and the licensed IP) that it is a specific ligand that can detect the Neu5Gc better than antibodies against Neu5Gc? If that is so, what are the antibodies directed against? Against the SubB2M? If so, does this mean that the CA125/SubB2M ELIZA does not work as promisingly as announced on 17 August 2021?
- Forums
- ASX - By Stock
- Ann: INOVIQ Awarded Additional BTB Funding to Develop SubB2M test
Monoclonal antibodies “for use in SubB2M immunoassays”, a vague...
-
- There are more pages in this discussion • 5 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add IIQ (ASX) to my watchlist
(20min delay)
|
|||||
Last
50.0¢ |
Change
0.010(2.04%) |
Mkt cap ! $46.00M |
Open | High | Low | Value | Volume |
49.0¢ | 50.0¢ | 47.5¢ | $35.73K | 73.13K |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
4 | 13954 | 47.5¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
50.0¢ | 6167 | 5 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 13954 | 0.475 |
1 | 4500 | 0.465 |
1 | 6000 | 0.460 |
2 | 35747 | 0.450 |
1 | 24390 | 0.410 |
Price($) | Vol. | No. |
---|---|---|
0.500 | 6167 | 5 |
0.510 | 6024 | 1 |
0.530 | 10000 | 1 |
0.540 | 10000 | 1 |
0.545 | 9300 | 2 |
Last trade - 15.55pm 21/05/2024 (20 minute delay) ? |
|
|||||
Last
50.0¢ |
  |
Change
0.010 ( 2.04 %) |
|||
Open | High | Low | Volume | ||
48.5¢ | 50.0¢ | 47.5¢ | 18914 | ||
Last updated 15.55pm 21/05/2024 ? |
Featured News
IIQ (ASX) Chart |
The Watchlist
AUQ
ALARA RESOURCES LIMITED
Stephen Gethin, Non-Executive Director & Chairman
Stephen Gethin
Non-Executive Director & Chairman
Previous Video
Next Video
SPONSORED BY The Market Online